Home » Stocks » GKOS

Glaukos Corporation (GKOS)

Stock Price: $94.56 USD 2.45 (2.66%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 4.25B
Revenue (ttm) 217.57M
Net Income (ttm) -73.12M
Shares Out 44.71M
EPS (ttm) -2.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $94.56
Previous Close $92.11
Change ($) 2.45
Change (%) 2.66%
Day's Open 92.88
Day's Range 91.06 - 97.49
Day's Volume 492,004
52-Week Range 23.31 - 98.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 days ago

Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Benzinga - 2 days ago

Glaukos Corp (NYSE: GKOS) has announced topline data from the U.S. Phase 3 trial evaluating its corneal cross-linking iLink therapy to treat keratoconus. Keratoconus is characterized by cone-s...

Zacks Investment Research - 3 days ago

Glaukos (GKOS) delivered earnings and revenue surprises of 93.75% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 days ago

Shares of Glaukos (NYSE:GKOS) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.02), which beat th...

Business Wire - 3 days ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Business Wire - 3 days ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Zacks Investment Research - 1 week ago

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 weeks ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Business Wire - 1 month ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Business Wire - 1 month ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Business Wire - 1 month ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Business Wire - 2 months ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Zacks Investment Research - 2 months ago

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Business Wire - 3 months ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Zacks Investment Research - 3 months ago

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

Zacks Investment Research - 3 months ago

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Seeking Alpha - 3 months ago

Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Glaukos (GKOS) delivered earnings and revenue surprises of 80.43% and 19.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Zacks Investment Research - 4 months ago

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Newsfile Corp - 5 months ago

San Diego, California--(Newsfile Corp. - September 29, 2020) - The Shareholders Foundation, Inc. announces that a lawsuit was filed for investors who formerly held Avedro, Inc. (AVDR) shares....

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow LLP, a leading investor rights law firm, announces it is investigating potential securities claims on behalf of former shareholders of Avedro Inc. (...

Zacks Investment Research - 5 months ago

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Business Wire - 5 months ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Seeking Alpha - 6 months ago

Glaukos Is Still A Good Long-Term Value Despite A Tough 2020

PRNewsWire - 6 months ago

SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Glaukos Corporation (NYSE: GKOS) ("Glaukos" or the "Company")...

Zacks Investment Research - 6 months ago

Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

Seeking Alpha - 6 months ago

Glaukos Corporation (GKOS) Tom Burns on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Glaukos (GKOS) delivered earnings and revenue surprises of 21.79% and 55.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 6 months ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Zacks Investment Research - 7 months ago

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 7 months ago

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c...

Zacks Investment Research - 8 months ago

Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

Zacks Investment Research - 8 months ago

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 9 months ago

Glaukos Corporation (GKOS) Tom Burns on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.

Zacks Investment Research - 9 months ago

Glaukos (GKOS) delivered earnings and revenue surprises of -25.71% and -0.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 10 months ago

Glaukos: Assessing The Value Proposition After Multiple Recent Deals

Zacks Investment Research - 11 months ago

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 11 months ago

Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.

Seeking Alpha - 1 year ago

Glaukos Corporation's (GKOS) Tom Burns on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APLT, APRE, BNTX, INMD, KRTX, NXTC, PLMR, RAPT, TPTX
Zacks Investment Research - 1 year ago

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.

Seeking Alpha - 1 year ago

Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Glaukos (GKOS) delivered earnings and revenue surprises of 41.18% and 3.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Acquisition news was the culprit behind the hit to shares of the ophthalmic medical technology and pharmaceutical company.

About GKOS

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use ... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Jun 25, 2015
CEO
Thomas Burns
Country
United States
Stock Exchange
NYSE
Ticker Symbol
GKOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for GKOS stock is "Buy." The 12-month stock price forecast is 73.30, which is a decrease of -22.48% from the latest price.

Price Target
$73.30
(-22.48% downside)
Analyst Consensus: Buy